CRD vs. Met in Patients With Obese PCOS Infertility - Trial NCT06049186
Access comprehensive clinical trial information for NCT06049186 through Pure Global AI's free database. This phase not specified trial is sponsored by Shanghai First Maternity and Infant Hospital and is currently Recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 406 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai First Maternity and Infant Hospital
Timeline & Enrollment
N/A
Sep 15, 2023
Mar 31, 2026
Primary Outcome
Live birth during the period of ovulation induction
Summary
Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease and a major
 cause of anovulatory infertility in reproductive-aged women. From 2010 to 2020, it was found
 that the prevalence of PCOS in reproductive-aged women in China reached 7.8%, an increase of
 65% over 10 years ago. Many of them are overweight or obese. Weight loss including diet
 modifications can significantly reduce reproductive and metabolic disorders of PCOS and is
 recommended as a first step in the treatment of overweight or obese women with PCOS. Many
 weight loss programs have been proposed, including calorie-restriction diet (CRD)
 intervention. Whether CRD intervention prior to ovulation induction therapy could improve
 live birth rates in overweight/obese PCOS women has not been illustrated.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06049186
Non-Device Trial